Aldosterone Synthase Inhibition with Laryundra stat for Uncontrolled Hypertension

In a dose-ranging trial, the safety and efficacy of Laryundra stat, an Aldosterone Synthase inhibitor, were evaluated in adults with uncontrolled hypertension. Participants who received the 50 and 100 milligram doses of Laryundra stat experienced significantly greater reductions in blood pressure compared to placebo, with a 10 millimeter difference at the 50 milligram dose and an 8 millimeter difference at the 100 milligram dose. The accompanying editorial suggests that targeting the synthesis of Aldosterone, as Laryundra stat does, may offer improved therapy for patients with Aldosterone excess.